BIOMARKERS IN THE EARLY DIAGNOSIS OF ACUTE KIDNEY INJURY IN CHILDREN (LITERATURE REVIEW)
Open Access
- 3 April 2025
- journal article
- Published by Higher State Educational Establishment of Ukraine Bukovinian State Medical University in Neonatology, surgery and perinatal medicine
- Vol. 15 (1(55)) , 158-165
Abstract
The diagnosis of acute kidney injury (AKI) is one of the most pressing issues in modern pediatrics. The classical method of diagnosing AKI is to determine the level of glomerular filtration rate, serum creatinine and diuresis. In the last 10-15 years, an active search and research of new biomarkers (BM) of acute kidney injury has been conducted. Aim of the study. To increase the awareness of pediatricians about the possibilities of using biomarkers in the early diagnosis and timely treatment of AKI in children based on the analysis of current literature. Materials and methods. A search of modern literature sources on medical portals such as UpToDate, PubMed, etc. on the use of BM in the early diagnosis of AKI in pediatric patients was performed. The data obtained were reviewed and analyzed. The results. The article presents a review of the current literature on the possibilities of using biomarkers of AKI in children in the early diagnosis of this pathology. Among the biomarkers of AKI are the following creatinine, urea, lipocalin associated with neutrophil gelatinase (NGAL); cystatin C, fractional solute excretion (FeS), ammonium (NH4)/ammonia (NH3), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), tissue inhibitor of metalloproteinase-2 (TIMP-2); insulin-like growth factor binding protein 7 (IGFBP 7); hepatic fatty acid binding protein (L-FABP); soluble urokinase plasminogen activator receptor (suPAR), Dickkopf 3 (DKK3), monocyte chemotactic peptide-1 (MCP-1), epidermal growth factor (EGF), fibroblast growth factor-23 (FGF-23), chemokine ligand 14 (CCL14), chitinase-3-like protein-1 (CHI3L1), uromodulin (Tamm-Horsfall protein), and α1-microglobulin (α1-M). Most of these AKI BMs are not widely used in daily clinical practice and require further investigation, making it prudent to increase the number of studies in this area. Conclusions. The presented materials will help to raise awareness among pediatricians and pediatric nephrologists about the possibilities of using modern biomarkers of AKI in children and expand the prospects for early diagnosis of this pathology, which will ensure the ability to detect the development of this syndrome in time and start effective treatment.Keywords
This publication has 41 references indexed in Scilit:
- The emerging role of CHI3L1 as a diagnostic marker and therapeutic target in allergic diseases and respiratory comorbiditiesAllergy Medicine, 2024
- Kidney urinary biomarkers in patients with branched‐chain amino acid and cobalamin metabolism defectsJournal of Inherited Metabolic Disease, 2023
- Lipocalin 2—not only a biomarker: a study of current literature and systematic findings of ongoing clinical trialsImmunologic Research, 2022
- Predictive value of suPAR in AKI: a systematic review and meta-analysisClinical and Experimental Nephrology, 2022
- Improving acute kidney injury diagnostic precision using biomarkersPractical Laboratory Medicine, 2022
- Serum and urinary biomarkers to predict acute kidney injury in premature infants: a systematic review and meta-analysis of diagnostic accuracyJournal Of Nephrology, 2022
- Early prediction of pediatric acute kidney injury from the emergency department: A pilot studyThe American Journal of Emergency Medicine, 2021
- The use of diagnostic tools for pediatric AKI: applying the current evidence to the bedsidePediatric Nephrology, 2021
- Dickkopf-3 in the prediction of contrast media induced acute kidney injuryJournal Of Nephrology, 2020
- Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medicationsPediatric Blood & Cancer, 2020